33 results about "High altitude hypoxia" patented technology

The invention provides a method for screening cattle high altitude hypoxia adaptation specific molecular marker, and furthermore a cattle kind or individual which is suitable for high altitude hypoxiasurvival is screened through the specific marker. The method aims at a high altitude hypoxia adaptation heredity characteristic of a kettle kind, and selects local cattle kinds which are distributedin high altitude regions at aspects of genome evolution, selecting and adapting. Multiple genome selecting signals, a full-genome association analysis method and a strategy are combined. Key genes andmolecular makers which are suitable for high altitude hypoxia are efficiently and accurately screened. Reasonable method designed is realized. The detecting method according to the key gene and marker designing has advantages of high accuracy, and convenient application operation. According to the method of the invention, through analyzing different altitude cattle kinds, a gene ACSS2 which is related with high altitude hypoxia adaptation and a haplotype thereof are found; and furthermore a specific SNP which bears a strongest selecting signal is positioned; and the method realizes an important meaning and a high practicability value for cattle molecule breeding operation.

The invention discloses application of cistanche phenylethanoid glycoside extractive to control altitude sickness. According to the application, experiments prove that the cistanche phenylethanoid glycoside extractive enables an organism to adapt to plateau anoxic environment and prevent encephaledema and pneumonedema from generating through anti-anoxia, anti-inflammatory, anti-oxidative stress and adjusting of aquaporin expression. Additionally, therapy medicine-administration experiments prove that the cistanche phenylethanoid glycoside extractive is capable of reducing incidence rate of limbs edema of a mouse attacked by chronic altitude sickness and mortality, and is capable of effectively reducing the pulmonary artery high pressure and the ventricle hypertrophy degree of a mouse attacked by chronic altitude sickness, and improving cardiopulmonary pathology change. Correspondingly, the invention also discloses a pharmaceutical composition containing the cistanche phenylethanoid glycoside extractive and being capable of controlling altitude sickness.

The invention provides a genetic marker relevant to the high altitude hypoxia adaptability of Tibetan sheep. The genetic marker is positioned on a PPAR (peroxisome proliferator activated receptor) alpha gene, and a concrete nucleotide sequence is as shown in a sequence table SEQ ID No. 1; in the nucleotide sequence of the sequence table SEQ ID No. 1, when an allelic gene is A, the high altitude hypoxia adaptability of the Tibetan sheep is poor; when the allelic gene is B, the high altitude hypoxia adaptability of the Tibetan sheep is good. The Tibetan sheep are taken as research objects, a PCR(Polymerase Chain Reaction)-SSCP (single-stranded conformational polymorphism) method is adopted to combine with DNA (deoxyribonucleic acid) sequencing technology so as to research the genetic variation characteristics of PPAR alpha genes of 2 sheep groups, and in the high altitude hypoxia adaptability, the molecular markers of the Tibetan sheep are initially screened out to provide foundation for subsequent relativity analyses.

The invention discloses a weariness-resistant anoxia-resistant health-care product composition. The weariness-resistant anoxia-resistant health-care product composition comprises hemicellulose, lacquer tree seed oil, soy protein isolate powder, a herbal rhodiola resea extract or herbal rhodiola sacra extract, spirulina, a panax notoginseng root extract, Chinese caterpillar fungus mycelium powder and a ginseng extract. The composition can increase the aerobic metabolism level of organisms, improve the oxygen utilization efficiency of cells, strengthen the altitude acclimatization capacity, and improve operation capacity under high altitude anoxia conditions; besides, the composition can also quickly complement sugar, fat, protein and other nutrients required by the organisms, promote nutrition absorption, rapidly fill carbohydrate and lost nutrients, which are consumed by profuse sweating during movement and particularly high-intensity movement training and exercising, and contribute to alleviating weariness of center and skeleton muscles, besides, is free from any toxic and side effects, and has significant efficacy of resisting weariness, resisting anoxia and adjusting immunity.

The invention discloses application of Codonopsis pilosula oligosaccharide in preparation of a medicine for preventing or treating gastrointestinal injury caused by anoxia. The anoxia is plateau anoxia and/or tissue ischemic anoxia. The invention also provides a preparation method of the Codonopsis pilosula oligosaccharide. The Codonopsis pilosula oligosaccharide has the following advantages: themedicine prepared by adopting the application of the Codonopsis pilosula oligosaccharide in the preparation of the medicine for preventing or treating gastrointestinal injury caused by anoxia has a very good effect, is safe and effective, and has no toxic or side effect; experimental verification shows that the medicine containing the Codonopsis pilosula oligosaccharide can improve spleen atrophyand pulmonary emphysema caused by high-altitude anoxiaof rats, enhance the anti-oxidation level, improve inflammations, relieve intestinal mucosal damage and reduce EPO expression; and protein expression detection further shows that the Codonopsis pilosula oligosaccharide can reduce the expression of HIF-1 alpha in duodenum of a high-altitude hypoxic rat.

The invention discloses a biomarker for detecting high altitude hypoxia and an application thereof. The biomarker for detecting the high altitude hypoxia is N-acetylneuraminic acid or a specific antibody thereof and used for preparing diagnostic reagent or a kit for detecting the high altitude hypoxia. The method of determining the degree of the high altitude hypoxia by detecting a serum marker helps to detect or assist in detecting hypoxia so as to help to take appropriate treatment measures as soon as possible, and is easy and fast in operation, easy for patients to accept, and convenient for the dynamical monitor of the progress of hypoxic injury in high altitude population.

The invention provides a method for establishing an acute high altitude anoxia and anxiety stress response animal model. The method comprises the following steps of (1) raising mice at conventional elevation environment, and performing cold water forced swimming adaptability training; (2) and then enabling the mice obtained in the step (1) to be exposed to high-elevation environmental conditions for raising, and performing high-elevation environment composite cold water forced swimming so as to obtain the acute high altitude anoxia and anxiety stress response animal model. The acute high altitude anoxia and anxiety stress response animal model obtained by the method disclosed by the invention has cerebral anoxia pathology characteristics that an aerobic metabolism way of sugar in brain tissues is blocked, so that the supply of ATP energy sources is obviously reduced, and lactic acid is accumulated, and behavioral expression of anorexia and enhanced anxiety behavior, and the induced stimulating factors and clinical pathology behavioral expression of the model both approach the actual situations of acute altitude stress response.

The invention relates to the technical field of natural medicines, and particularly relates to a method for preparing a medicine with an areca-nut component and anti-hypoxic application of the medicine. Overall animal tests show that an areca-nut extract has remarkable anti-hypoxic activity, and can not only prolong the survival time of hypoxia mice in a sealed normal pressure space, but also improve the high altitude anoxia resistance of hypoxia rats acutely entering into a real altitude situation. The mechanism is possibly related to effects that the minute ventilation volumes of the rats are increased, excessive free radicals in tissue are eliminated and the oxidation resistance is improved. The areca-nut extract is a natural component, is free of toxic or side effect on animals and human bodies and is applicable to anti-hypoxic application.

The present invention relates to an application of pyrroloquinoline quinone (PQQ) in the preparation of a medicament used for preventing and treating acute altitude sickness and acute altitude hypoxia injury. Pyrroloquinoline quinone has the effect of preventing and treating acute high altitude hypoxia injury, and as a drug for the prevention and treatment of acute altitude sickness, the efficacy thereof is equivalent to that of acetazolamide, however acetazolamide has many toxic side effects; meanwhile, as a coenzyme, pyrroloquinoline quinone has the advantages of low toxicity and is easily acceptance by patients. In addition, by means of exhaustive swimming experiments of mice under the conditions of hypoxic exposure, PQQ has been shown to have the feature characteristics of improving the working capabilities of a subject at a high altitude, however acetazolamide has not been found to have said effect.

The invention discloses a novel application of sodium sulfite (Na2SO3), that is, an application in preparing medicines, health products, functional drinks or functional food for preventing hypoxia-induced injury and/or diseases related to ischemia-hypoxia. According to the invention, by using Na2SO3 as an active component in preparing medicines, health products, functional drinks or functional food for preventing hypoxia-induced injury and/or diseases related to ischemia-hypoxia, the body can be in a hypoxia (such as high altitude hypoxia, mine hypoxia, and the like ) preconditioning state, thus the purpose of preventing hypoxia-induced injury and/or diseases related to ischemia-hypoxia (such as high altitude pulmonary edema, high altitude cerebral edema, cerebral ischemia, cardiac ischemia, respiratory distress, and the like) can be achieved. The medicines disclosed herein have the following advantages: 1) obvious curative effect; 2) no toxic and side effect, and high safety; 3) low price of Na2SO3; and 4) convenience in drug use (convenience in carrying and taking).

The invention relates to an alpha D globin gene as a chicken molecular mark with high oxygen carrying capability as well as a detection method and application thereof, belonging to the technical field of auxiliary selection of chicken genetic markers. The nucleotide sequence of the molecular mark provided by the invention is shown as SEQ ID No: 1, wherein the 251 bp in the sequence has an A/C base mutation which is recorded as A251C and causes BSEG I-RFLP Polymorphism. The sequence of a primer for amplifying the molecular marker is shown as SEQ ID No: 2 and SEQ ID No: 3. The method for detecting the molecular marker comprises the steps of extraction of chicken genome DNA in a sample to be detected, PCR amplification and the enzyme digestion of a restriction enzyme BSEGI of the PCR product. When the genotype of a chicken individual to be detected is CC type (478bp+35bp), the chicken individual has high oxygen carrying capability. The invention provides the effective molecule marker for breeding excellent cross-fertilizer chickens which adapt to high altitude hypoxia environments and has high yield and high quality.

The invention belongs to the technical field of genetic biology, and particularly relates to a structural variation molecular marker related to goat hypoxia adaptation and application. The structural variation molecular marker is located at 245bp insertion/deletion at the 42098934th basic group of the 26th chromosome of a goat, particularly insertion/deletion at the 98bp of a nucleotide sequence as shown in SEQ ID No. 1, and the nucleotide sequence of insertion/deletion is as shown in SEQ ID No. 2. The invention also provides a specific primer pair and a detection method for detecting the molecular marker with the structural variation. The sequence of the specific primer pair is shown as SEQ ID No.3 and SEQ ID No.4. The invention also provides a detection method for detecting the molecular marker with the structural variation. The molecular marker with the structural variation is not limited by factors such as age and sex of goats, and can be used for introducing goats with high altitude hypoxia adaptability and breeding varieties.

The invention relates to an ozone reduction device for high altitude hypoxia. The ozone reduction device includes an oxygen reduction unit 2 which consists of two closed containers 9 and 10 having inlets and outlets; the outlet of the first closed container 9 communicates with the inlet of the second closed container 10 through a pipe; a laser irradiator 6 is arranged in the first closed container 9; an ozone reducing agent 8 selected from one or all of iodine and catalyst chloride ions is added in the second closed container 10; and the oxygen reduction unit 2 may be characterized in that the laser irradiator 6 is arranged in a closed container 5 having an inlet and an outlet, a heater 7 is arranged on the closed container 5, and the ozone reducing agent 8 selected from one or all of the iodine and the catalyst chloride ions is added in the closed container 5. The ozone reduction device is compact in structure, is easy to operate, is safe and reliable, is easy to assemble, is low in cost, is portable, can avoid pollutants, can clean air, and can protect an environment.

The invention discloses application of morinda officinalis oligosaccharides in preparation of drugs for treating body dysfunction caused by high-altitude anoxia. The morinda officinalis oligosaccharides can be used for improving anoxic tolerance and fatigue resistance and can also be used for alleviating intracerebral inflammatory reactions; and the morinda officinalis oligosaccharides can also be used for treating body nerve-immunity-endocrine disorders caused by high-altitude brain injury and the high-altitude anoxia and treating body hypofunction and injury caused by the aspects of cognition, emotions and physical performance.